Imagion Biosystems - Nanoparticle-based imaging technology
Imagion Biosystems focuses on the development of new medical imaging techniques using magnetic nanoparticles to identify and diagnose cancer. The company aims to disrupt the cancer diagnosis market, which it estimates is worth US$100bn annually, with its non-invasive and non-radioactive MagSense imaging platform. Imagion’s technology is in Phase I trials for the detection of HER2 positive metastatic breast cancer. In 2019, the FDA awarded the MagSense platform Breakthrough Device status, offering a potentially faster time to market.Imagion Biosystems is engaged in the following activities: nanotechnology, biotechnology, cancer diagnostics, and superparamagnetic relaxometry.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.